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AKT activation is associated withmanymalignancies,
where AKT acts, in part, by inhibiting FOXO tumor
suppressors. We show a converse role for AKT/
FOXOs in acute myeloid leukemia (AML). Rather than
decreased FOXO activity, we observed that FOXOs
are active in40%ofAMLpatient samples regardless
of genetic subtype. We also observe this activity in
human MLL-AF9 leukemia allele-induced AML in
mice, where either activation of Akt or compound
deletion of FoxO1/3/4 reduced leukemic cell growth,
with the latter markedly diminishing leukemia-initi-
ating cell (LIC) function in vivo and improving animal
survival. FOXO inhibition resulted in myeloid matura-
tion and subsequent AML cell death. FOXO activation
inversely correlated with JNK/c-JUN signaling, and
leukemic cells resistant to FOXO inhibition responded
to JNK inhibition. These data reveal a molecular role
for AKT/FOXO and JNK/c-JUN inmaintaining a differ-
entiation blockade that can be targeted to inhibit
leukemias with a range of genetic lesions.
INTRODUCTION
The serine/threonine kinase AKT is a highly conserved central
regulator of growth-promoting signals in multiple cell types.
Deregulation of AKT has been associated with multiple human
diseases including a wide variety of cancers (Altomare and
Testa, 2005; Nicholson and Anderson, 2002). AKT functions by
phosphorylating and inactivating substrates that antagonizecell growth and survival, including PRAS40, GSK-3b, TSC2,
BAD, and FOXOs (Brunet et al., 1999; Cross et al., 1995; Datta
et al., 1997; del Peso et al., 1997; Inoki et al., 2002; Kops et al.,
1999; Sancak et al., 2007). The kinase activity and substrate
selectivity of AKT are principally controlled by phosphorylation
of threonine 308 (pAKTThr308) and serine 473 (pAKTSer473) (Alessi
et al., 1996). pAKTSer473 is dispensable for AKT-mediated phos-
phorylation of TSC2 and GSK-3b, whereas pAKTSer473 is
required for phosphorylation and inactivation of the FOXOs
(Guertin et al., 2006).
Direct mutations in components of the PI3K signaling pathway
are rarely observed in humanAML; however, elevated AKT phos-
phorylation has been observed in 50% (Park et al., 2010).
pAKTThr308 was shown to confer a poor prognosis in AML (Gallay
et al., 2009), whereas pAKTSer473 correlates with a favorable
response to chemotherapy (Tamburini et al., 2007). In mouse
models, constitutive activation of Akt or deletion of Pten, which
suppresses Akt signaling, leads to myeloid or lymphoid
neoplasia (Kharas et al., 2010b; Yilmaz et al., 2006). Collectively,
these observations have supported the general concept that
activated AKT signaling is associated with hematopoietic
malignancies.
The FOXO family of transcription factors comprises four highly
related members—FOXO1, FOXO3, FOXO4, and FOXO6—that
are direct downstream targets of AKT (Arden, 2006; Brunet
et al., 1999; Kops et al., 1999; Fu and Tindall, 2008). In the
absence of active AKT, FOXOs localize to the nucleus where
they regulate the transcription of genes involved in cell-cycle
arrest, apoptosis, and reactive oxygen species (ROS) detoxifica-
tion. Paradoxically, although FOXOs are primarily known as
tumor suppressors, high FOXO3 expression is associated with
adverse prognosis in AMLs exhibiting normal cytogenetics (San-
tamarı´a et al., 2009). Furthermore, genetic ablation of FoxO3Cell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc. 697
reduced disease burden in a murine model of chronic myeloid
leukemia (CML) (Naka et al., 2010).
AMLs are genetically heterogeneous malignant neoplasms
that have a low survival rate (Fro¨hling et al., 2005). AML prog-
nosis is dependent on the cytogenetic and molecular profiles
of AML cells (Armstrong et al., 2003; Dash and Gilliland, 2001;
Do¨hner et al., 2010). The genetic and molecular diversity
observed in AML has made the development of universal or
broad AML-targeted therapies very difficult. Thus, investigation
of the molecular signatures that separate AMLs into larger,
more discrete groups is needed to develop more general and
effective therapies.
We used human samples to assess the potential for AKT/
FOXO signaling to divide AML into broad groups, and we used
both an established murine model and human AML cells to
define whether targeting AKT/FOXO could affect disease. We
unexpectedly observed that low levels of AKT activity associated
with elevated levels of FOXOs are required to maintain the func-
tion and immature state of leukemia-initiating cells (LICs).
Furthermore, depletion of FOXO3 promoted differentiation and
apoptosis of human myeloid leukemia cells. These data reveal
an unrecognized role of the AKT/FOXO signaling pathway in
the regulation and maintenance of AML that runs counter to
the established roles of AKT/FOXO signaling in human cancer.
Finally, we also observed that inhibition of FOXO, either directly
or via AKT activation, stimulates the JNK/c-JUN pathway, which
suppresses AML cell apoptosis. These findings provide unique
molecular insights into how growth-control pathway perturba-
tion can participate in malignancy and identify specificmolecular
targets for differentiation-inducing approaches to a large propor-
tion of myeloid leukemias.
RESULTS
AKT Activity Is Diminished in MLL-AF9 CD34+ Myeloid
Progenitors
Because specific modifications of AKT confer distinct clinical
outcomes of human AML (Gallay et al., 2009; Park et al., 2010;
Tamburini et al., 2007), we examined Akt status in a murine
model of MLL-AF9-induced myeloid leukemia that closely phe-
nocopies human AML (Krivtsov et al., 2006). In this model, the
L-GMP (leukemia-granulocyte macrophage progenitor) cell pop-
ulation, which shares the same immunophenotype of GMPs (lin-
eagelow, cKithigh, Sca-1, FcgRII/III+, CD34+), is enriched for LIC
activity. Akt phosphorylation was assessed by flow cytometry in
cells from healthy and MLL-AF9 leukemic mice. Normal myeloid
progenitors displayed a robust increase in both pAktSer473 and
pAktThr308 (Figure 1A and Figure S1A available online); however,
leukemic progenitors (enriched for L-GMPs) exhibited markedly
reduced pAktSer473 and pAktThr308 in response to stimulation,
indicating attenuated Akt activation (Figure 1A and Figure S1A).
Cells were further evaluated for serine 235/236 phosphorylation
of ribosomal S6 (pS6Ser235/236), a downstream effector of AKT
signaling (Burgering and Coffer, 1995). Normal CD34+ cells
showed strong induction of pS6Ser235/236 (Figure S1B), whereas
CD34+ leukemic progenitors had a blunted pS6Ser235/236
response, further demonstrating that Akt activity is diminished
in MLL-AF9 LIC-enriched populations (Figure S1B).698 Cell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc.Constitutive Activation of Akt Promotes Myeloid
Differentiation and Apoptosis of Murine AML Cells
The diminished Akt activity in MLL-AF9-driven LICs and BCR-
ABL-positive LICs (Naka et al., 2010) prompted us to determine
the biological consequences of enforcing Akt activity in MLL-
AF9-positive AML cells. To that end, bone marrow (BM) cells
from MLL-AF9 leukemic mice were adapted to liquid culture
and infected with recombinant retroviruses expressing a consti-
tutively active form of Akt (myr-Akt). Cells expressing myr-Akt
had markedly impaired proliferation compared to control-in-
fected cells (Figure 1B), consistent with previous reports (Wang
et al., 2008). Ablation of Pten (an inhibitor of Akt signaling) in
the murine hematopoietic system results in the rapid onset of
myeloid and/or lymphoid neoplasia (Lee et al., 2010; Yilmaz
et al., 2006). Within this model, leukemogenesis is largely depen-
dent on mammalian target of rapamycin (mTor) signaling, as ra-
pamycin markedly delays disease onset (Yilmaz et al., 2006).
Enforced expression of myr-Akt strongly increased the phos-
phorylation of mTor substrates (Figure S1D). However, treatment
of myr-Akt-expressing AML cells with effective concentrations of
rapamycin did not completely rescue the cell growth defect (Fig-
ure 1B and Figure S1C). Although these results do not exclude
a role for mTor signaling, they do suggest that additional mech-
anisms might contribute to the cell growth defect associated
with myr-Akt expression in murine AML cells.
Expression of myr-Akt in normal bone marrow reduces the
self-renewal properties of normal hematopoietic stem and
progenitor cells (HSPCs) and promotes myeloid maturation
(Kharas et al., 2010b). Therefore, we examined whether myr-
Akt expression was inhibiting AML cell growth by promoting
myeloid maturation. myr-Akt cells displayed increased forward
and side scatter by cytometry, consistent with mature myeloid
cells (Figure S1E). Further, mature myeloid cell markers
(CD11b) were higher on myr-Akt cells (Figure 1C), and myr-Akt
cells exhibited morphological changes of myeloid maturation
including reduced nucleoli, increased cytoplasmic volume, gran-
ule formation, and condensed chromatin (Figure 1D). Finally,
myr-Akt cells acquired the ability to engulf fluorescent-labeled
bacterial peptides, confirming the myr-Akt-directed maturation
of leukemic blasts into functional myeloid cells with the capacity
for phagocytosis (Figures 1E and 1F).
Upon completion of myelopoiesis, mature myelocytes have
a limited life span in the peripheral blood. Therefore, we evalu-
ated whether myr-Akt-induced maturation of myeloid cells is
accompanied by increased cell death. Apoptosis was increased
in myr-Akt myeloid cells (Figure 1G). Maturation-related death
mediated by myr-Akt occurred in the presence of rapamycin,
suggesting that Akt utilizes pathways other than mTor activation
for myeloid maturation (Figures 1C–1F). Together, these results
suggest that LICs within this model maintain low levels of Akt
activity to preserve an immature cell state by preventing differen-
tiation and death.
FoxOs Are Active in Murine MLL-AF9 L-GMPs
FoxOs play central roles in regulating normal hematopoiesis and
are integral mediators of Akt’s actions in cellular growth and
survival (Fu and Tindall, 2008; Miyamoto et al., 2007; Tothova
et al., 2007; Yalcin et al., 2008). We evaluated FoxO activity in
Figure 1. Constitutive Akt Activation Promotes Myeloid Maturation and Apoptosis of Leukemic Cells
(A) Lineagelow, Sca-1, cKithigh, CD34+ cells purified from healthy and leukemic mice were stimulated with or without mSCF and then subjected to flow cytometry
with phospho-AktSer473 (CD34+ myeloid progenitors [MP] versus CD34+ leukemic progenitors [LP], p = 0.0478). Right panel is a histogram from a single
experiment with the left panel representing mean ± standard error of the mean (SEM) from three experiments.
(B) Mononuclear bone marrow cells (MNBCs) recovered from MLL-AF9 leukemic mice were infected with MSCV-IRES-GFP control (Ctrl) or myr-Akt-expressing
retroviruses. Cells from each condition were then treated with vehicle or 10 nM or 100 nM rapamycin and evaluated for numbers of GFP+ cells every 2 days using
flow cytometry (day 6 *Ctrl versus myr-Akt, vehicle, p = 0.0005; **Ctrl versus myr-Akt, 10 nM rapamycin, p = 0.0008; ***Ctrl versus myr-Akt, 100 nM rapamycin,
p = 0.0046; n = 3). Data are represented as the mean ± standard deviation (SD).
(C) GFP+ cells treated as described above were analyzed for CD11b expression (*Ctrl versus myr-Akt, vehicle, p < 0.0001; **Ctrl versus myr-Akt, 10 nM rapa-
mycin, p < 0.0001; *** Ctrl versus myr-Akt, 100 nM rapamycin, p < 0.0001; n = 3) or (D) stained with May-Gru¨nwald Giemsa. Data are represented as the
mean ± SD.
(E and F) Flow cytometric analysis of control andmyr-Akt-infected cells incubated with pHrodo fluorescent-labeled E. coli particles. (E) Flow cytometric histogram
plot of pHrodo-stained Ctrl versus myr-Akt GFP+ cells and (F) graphical representation of three replicates (*Ctrl versus myr-Akt, vehicle, p < 0.0001; **Ctrl versus
myr-Akt, 10 nM rapamycin, p < 0.0001; ***Ctrl versus myr-Akt, 100 nM rapamycin, p = 0.0009; n = 3). Data are represented as the mean ± SD.
(G) Flow cytometric analysis of Annexin V expression on Ctrl and myr-Akt-expressing cells (*Ctrl versus myr-Akt, p = 0.0006; n = 3). Data are represented as the
mean ± SD.
See also Figure S1.L-GMPs by assessment of several well-established FoxO target
genes. Cdkn1b (p27), Cited2, Ccrn4l, Meis1, Tmem71, and
Ccng2 are all activated by FoxOs and were found to be upregu-
lated in L-GMPs compared to GMPs (Figure 2A). Ccnd1, Ccnd2,
Atm, and Sox4, which are repressed by FoxOs, were docu-
mented to be downregulated in L-GMPs (Figure 2A).Because AKT-mediated phosphorylation of FOXOs leads to
nuclear exclusion and subsequent inactivation (Brunet et al.,
1999), the nuclear localization of FoxO3 (the dominant FoxO
family member active in the murine hematopoietic system;
Miyamoto et al., 2007; Yalcin et al., 2008) was evaluated in
normal GMPs and L-GMPs by immunofluorescence. FoxO3Cell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc. 699
Figure 2. FoxOs Are Active and Suppress Myeloid Maturation in Murine AML Cells
(A) Table of activated (left panel) and repressed (right panel) FoxO target genes differentially expressed between GMP and L-GMP microarray datasets (D-Chip
analysis, p = 0.95).
(B) Immunofluorescence of purified lineagelow, Sca-1, cKithigh, CD34+, FcgRII/III+ cells from healthy and MLL-AF9-induced leukemic mice with FoxO3-specific
antibodies (75D8) and DAPI contrast.
(C) Mononuclear bonemarrow leukemia cells expressingMLL-AF9 and bearing floxed alleles for FoxO1, FoxO3, and FoxO4 (FoxO1/3/4floxed;MLL-AF9 cells) were
infected with Ctrl or CreER-expressing recombinant retroviruses and then treated with vehicle or 400 nM 4-hydroxytamoxifen (4-OHT) for 4–6 hr. 48–72 hr
following treatment, cells from all conditions were subjected to western blotting with FoxO3, Tubulin, and Cre antibodies.
(D) Five days following treatment, Ctrl and CreER cells from each condition were assessed by flow cytometry for CD11b and Gr-1 expression (*CreER + 4-OHT
versus CreER + vehicle, Ctrl + vehicle, or Ctrl + 4-OHT, p < 0.0001; n = 3, data represented as the mean ± SEM) and (E) stained with May-Gru¨nwald Giemsa.
See also Figure S2.was predominantly cytoplasmic in GMPs, whereas L-GMPs
displayed nuclear localization of FoxO3 (Figures 2B). Collec-
tively, these data suggest that FoxOs are active in L-GMPs but
do not exclude that they are also active in other AML cellular
subsets.
Deletion of FoxOs Promotes Myeloid Maturation
of Murine AML Cells
Next, we sought genetic evidence for an active role of FoxOs in
the maintenance of the differentiation blockade of leukemic
cells. BM cells recovered frommice bearing homozygous floxed
alleles of FoxO1, FoxO3, and FoxO4 (FoxO1/3/4floxed) were
transduced with recombinant retroviruses expressing human
MLL-AF9. FoxO1/3/4floxed;MLL-AF9 leukemic BM cells were
then engineered to stably express the CreER fusion protein,
thus allowing for inducible excision of FoxO1/3/4floxed alleles
ex vivo (Figure 2C). FoxO1/3/4floxed;MLL-AF9 leukemic cells
stably expressing CreER were cultured in the presence and
absence of 4-hydroxytamoxifen (4-OHT) and monitored for
changes in immunophenotype and morphology. Deletion of
FoxO1/3/4 resulted in increased surface expression of the
maturemyeloid cell markers CD11b andGr-1 (Figure 2D and Fig-
ure S2A). Ablating FoxO1/3/4 also induced morphological
changes consistent with myeloid maturation (Figure 2E and Fig-
ure S2B). The myeloid maturation observed with FoxO1/3/4
deletion was associated with gene ablation and not Cre ex-
pression alone (Figures S2C and S2D). Finally, deletion of
FoxO1/3/4 diminished the ability of FoxO1/3/4floxed;MLL-AF9700 Cell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc.leukemic cells to form and maintain colonies on supportive
stroma (Figures S2E and S2F). Together, these data indicate
that FoxO1/3/4 deficiency promotes myeloid maturation, mirror-
ing the activated Akt phenotype.
Depletion of FOXO3 Promotes Myeloid Maturation and
Apoptosis of Human AML Cell Lines
To determine whether FOXO3 is also active in human AML cell
lines carrying MLL-AF9 translocations, the cytoplasmic and
nuclear fractions of THP-1 and Mono-mac-6 (MM6) cells were
evaluated for FOXO3 expression. Similar to our murine model,
FOXO3 was nuclear in these human AML cell lines with approx-
imately equal distribution between the two cellular compart-
ments. Furthermore, SKM-1 cells as well as a human acute pro-
myelocytic leukemia (APL) cell line (NB4), neither of which bear
MLL translocations, displayed 75% and 86% nuclear FOXO3,
respectively, suggesting that FOXO3 may serve comparable
biological roles in other forms of AML (Figure 3A).
To determine human AML dependence on FOXOs, we used
FOXO3 shRNA in cell lines with MLL-AF9 translocations
(MOLM-14, THP-1, MM6, and NOMO-1), APL cell lines (HL-60
and NB4), and AML cell lines that do not carry MLL transloca-
tions (SKM-1 and U-937) (Figure 3B and Figure S3A). All eight
cell lines expressing FOXO3 shRNA exhibited lower growth rates
compared to control shRNA-expressing cells (Figure 3C and Fig-
ure S3B). Depletion of FOXO3 resulted in increased CD11b
expression (Figure 3D and Figure S3C) and morphological
changes consistent with myeloid maturation (Figure 3F and
Figure 3. FOXO3 Is Active and Required to Preserve the Immature State of Human AML Cell Lines
(A) THP-1 and Mono-mac-6 (MM6) (both MLL-AF9+) and SKM-1 and NB4 (both MLLAF9) leukemia cell lines were fractionated into nuclear (N) and cytoplasmic
(C) extracts and subjected to western blotting with FOXO3, ORC2 (nuclear), and Tubulin (cytoplasmic) antibodies.
(B) MOLM-14,MM6, and SKM-1 cells were stably transduced with recombinant lentiviruses expressing either nontargeting (NT) or FOXO3 (F3-1 or F3-2) shRNAs.
Cells were then subjected to western blotting with FOXO3 and Tubulin antibodies or (C) counted either everyday (SKM-1 and NB4) or every 2 days (MOLM-14 and
MM6) following stable expression of designated shRNAs (day 6 MOLM-14, NT versus F3-1, *p = 0.0003; NT versus F3-2, **p < 0.0001; day 6 MM6, NT versus
F3-1, *p < 0.0001; NT versus F3-2, **p = 0.0002; day 4 SKM-1, NT versus F3-1, *p = 0.0062; NT versus F3-2, **p = 0.0083; day 4 NB4, NT versus F3-1, *p = 0.0003;
NT versus F3-2, **p = 0.0058). Data are represented as the mean ± SD.
(D) Transduced MOLM-14 and SKM-1 cells were analyzed by flow cytometry for human CD11b expression (MOLM-14, NT versus F3-1, *p < 0.0001; NT versus
F3-2, **p < 0.0001; SKM-1, NT versus F3-1, *p < 0.0001; NT versus F3-2, **p = 0.0115). Data are represented as the mean ± SD.
(E) Flow cytometric analysis of transduced MM6 cells incubated with pHrodo particles.
(F) May-Gru¨nwald Giemsa staining of transduced MOLM-14, SKM-1, and NB4 cells.
(G) Flow cytometric analysis of transduced SKM-1 cells stained with Annexin V and CD11b (*NT shRNA versus FOXO3 shRNA-1, CD11b+, p < 0.0001; **NT
shRNA versus FOXO3 shRNA-2, CD11b+, p = 0.0007; n = 3). Data are represented as the mean ± SD.
NT = NT shRNA, F3-1 = FOXO3 shRNA-1, and F3-2 = FOXO3 shRNA-2; n = 3. See also Figure S3.Figure S3E). Knockdown of FOXO3 also enhanced the phago-
cytic capabilities of MOLM-14 and MM6 cells (Figure 3E and
Figure S3D). Finally, CD11b+ cells expressing FOXO3 shRNAs
displayed a marked increase in apoptosis (Figure 3G and Fig-ure S3F). Depletion of FOXO3 did not reduce cell numbers,
increase mature myeloid surface markers, or alter the phago-
cytic properties (Figures S3A, S3B, and S3D) of the BCR-ABL-
positive cell line K562.Cell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc. 701
Figure 4. Primary AMLs Derived from Patients Separate into Distinct Clusters of FOXO Activity
(A) BM cells derived from patients with AML were stained with human lineage cocktail and human CD34 (both BD Biosciences), and then lineagelow, CD34+ cells
were isolated by flow cytometry. Nuclear (N) and cytoplasmic (C) extracts of total MNBCs (TBM) and lineagelow, CD34+ cells were subjected to western blotting
with FOXO3, ORC2, and Tubulin antibodies.
(B) Lineagelow, CD34+ cells from three AML patients analyzed as described above.
(C) Patient samples #1 and #6 were transduced with recombinant lentiviruses expressing either NT shRNA or FOXO3 shRNA-1, then grown in liquid culture for
8 days, and then assessed for CD11b expression. Bar graphs are represented as the mean ± SD.
(D) Transduced patient samples #1 and #6 cells were placed in methylcellulose supplemented with human cytokines. Graph represents the enumeration of
colonies formed after 8 days of culture. Data are represented as the mean ± SD.
(E) Transduced cells from patient sample #1 stained with Wright-Giemsa after 8 days of liquid culture.
(F) Gene list comprising the FOXO-specific gene signature generated from comparing the gene expression array data of murine lineagelow, Sca-1+, cKit+ (LSK)
cells in animals without (+/+) and with (D/D) FoxO1/3/4 deletion (comprehensive gene set located in Table S1).
(G) Hierarchical cluster analysis based on the overlap of the murine FOXO gene signature stratified over the gene expression array data of 436 individual primary
AML samples.
See also Figure S4 and Table S1.FOXO3 Is Activated in Primary AMLs Derived from
Patients
To validate our findings in AML cell lines, the cellular distribution
of FOXO3 was examined in primary BM cells derived from nine
different AML patients. Biochemical fractionation displayed
a wide variation between samples in the nuclear-to-cytoplasmic
ratio of FOXO3 (3%–70% nuclear FOXO3) (Figures 4A and 4B;
Figures S4A and S4B). Five of the nine samples contained
CD34+ blasts. Fluorescence-activated cell sorting (FACS) isola-
tion of the CD34+, lineagelow population revealed enrichment for
nuclear FOXO3 in comparison with fractionation of the total BM
or CD34, lineagehigh cells (Figure 4A and Figure S4A). Within702 Cell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc.these five samples, the overall level of nuclear FOXO3 varied
between 10%–70%. Depletion of FOXO3 reduced colony forma-
tion in methylcellulose and promoted myeloid maturation (by
surface marker expression and morphology) in two samples
(Figures 4C–4E).
To determine the global status of FOXO activity in AML, gene
expression array data from murine hematopoietic stem cells
(HSCs) with and without FoxO1/3/4 (Tothova et al., 2007) were
utilized to generate a hematopoietic-specific gene signature of
FOXO activity (Figure 4F; Table S1). Using this FoxO target
gene set, unsupervised hierarchical clustering analysis of 436
primary AML samples was performed (Bullinger et al., 2004;
Kharas et al., 2010a). The differential expression of FOXO target
genes stratified AML into two distinct clusters, strongly suggest-
ing that these clusters reflect two distinct patterns of FOXO
activity; cluster 1 AMLs display lower FOXO activity relative to
AMLs within cluster 2 (Figure 4G). Consistent with this notion,
FOXO1 and FOXO3 expression in cluster 2 (higher FOXO activity)
is significantly elevated compared to cluster 1 (lower FOXO
activity) (p < 0.0001; Figure 7C). Each cluster was significantly
represented in nine AML subgroups separated on the basis of
defined chromosomal aberrations, indicating that FOXO acti-
vation is not restricted to a particular subtype of AML (p <
0.0001; Figure S4C). However, AMLs bearing FLT3-ITD muta-
tions (associated with poor prognosis) were underrepresented
in the cluster 2 (higher FOXO activity) gene signature (p <
0.0001; Figure S4D). Combined, these analyses extend the
importance of FOXOs beyond MLL-AF9+ AMLs and suggest
that FOXOs may impact a broad spectrum of myeloid leukemias
of various genotypes.
MLL-AF9 Leukemic Burden Is Reduced in the Absence
of FoxO1/3/4 In Vivo
To address whether FoxO1/3/4 are essential to maintain MLL-
AF9-induced AML in vivo, we used a MLL-AF9 bone marrow
transplant (BMT) assay in a mouse bearing homozygous Lox-P
flanked (floxed) alleles of FoxO1/3/4 and the interferon-inducible
Mx1-Cre transgene (FoxO1/3/4floxed;Mx1-Cre+;MLL-AF9—
hereafter Cre+). MLL-AF9-transformed FoxO1/3/4floxed BM cells
without theMx1-Cre transgene (FoxO1/3/4floxed;Mx1-Cre;MLL-
AF9—hereafter Cre) were used as controls. Leukemia cells
recovered from primary recipients displaying frank leukemia
were transplanted into sublethally irradiated recipients. Fourteen
days post-transplant, Cre and Cre+ secondary recipients were
administered polyinosine-polycytidyline (pI-pC) to induce exci-
sion of FoxO1/3/4 floxed alleles or saline control (Figure 5A). At
the first presentation of AML, all mice from each group were
euthanized and assessed for leukemic burden as defined by
spleen weight and peripheral white blood cell (WBC) counts.
Saline- and pI-pC-treated Cre and saline-treated Cre+ recipi-
ents all developed splenomegaly and leukocytosis (Figures
5B–5D; Figure S5A). In contrast, pI-pC-treated Cre+ trans-
planted mice retained normal spleen weights and WBC counts
(Figures 5B–5D; Figure S5A).
To distinguish whether disrupting FoxO1/3/4 expression elim-
inated MLL-AF9 leukemia or merely delayed the onset, we eval-
uated the survival rates of Cre andCre+ recipientmice that were
given saline or pI-pC. Blood from recipient mice was analyzed
every 4–14 days. Consistent with the prior findings, pI-pC-
treated Cre+ mice had lower WBC counts than saline-treated
controls (Figure 5D). Regardless of pI-pC treatment, recipient
mice transplanted with Cre leukemic cells or those transplanted
with saline-treated Cre+ cells had similar latencies for AML
(Figures 5E and 5F). In contrast, mice transplanted with pI-pC-
treated Cre+ leukemic cells (FoxO1/3/4 deleted) displayed
a significantly longer latency. Interestingly, 20% of mice (n =
10) were disease free up to 5 months post-excision. However,
despite efficient excision of FoxO1/3/4 (Figures S5C–S5F), the
majority of mice eventually succumbed to leukemia (Figure 5F),
the basis for which we subsequently discovered as noted below.Collectively, these in vivo studies show that one or more of
FoxO1/3/4 support MLL-AF9-induced leukemia.
FoxO1/3/4 Are Required for LIC Function In Vivo
The LIC population represents a small subset of AML cells that
retain the ability to give rise to leukemia in recipient mice.
Because the L-GMP population of this AML model is enriched
for LICs, we first assessed how the deletion of FoxO1/3/4
affected L-GMP frequency. Specifically, Cre+ recipient mice
were administered pI-pC (D/D) or saline (+/+) 14 days post-trans-
plantation. Seven days following pI-pC treatment, BM cells were
analyzed and a reduction in L-GMPs with a concomitant
increase of lineagehigh, CD11bhi myeloid cells was noted (Figures
5G and Figure S5G).
To test whether loss of FoxO1/3/4 also diminished LIC func-
tion, we performed a limit dilution assay. Leukemic BM cells
from Cre+ mice 7 days following pI-pC or saline treatment
were transplanted into recipients at cell doses of 33 102,3 103,
3 104, 3 105/animal. On day 130 post-transplantation, 17%,
50%, 100%, 100%, respectively (corresponding to the cell
doses above), of saline-treated Cre+ (+/+) mice succumbed to
AML (LIC frequency = 1:5,314; Figure 5H). In contrast, 0%,
0%, 25%, 100%, respectively, of mice transplanted with
pI-pC-treated Cre+ (D/D) donor cells developed AML (LIC
frequency = 1:86,044), an 16-fold reduction in LIC frequency
(Figure 5I). Furthermore, mice transplanted with 300,000 Cre+
(D/D) cells displayed nearly a 2-fold increase in median survival
over mice transplanted with Cre+ (+/+) donor cells (median
survival 43 versus 82 days, Figures 5H and 5I), consistent with
FoxO1/3/4 deletion significantly extending the latency of MLL-
AF9-positive AML in vivo (n = 4, p = 0.0007). Additionally, mice
reconstituted with donor cells from Cre+ (D/D) mice from Fig-
ure 5F displayed an extended latency in comparison with recip-
ients transplanted with donor cells fromCre+ (+/+) leukemicmice
in Figure 5F (Figure S5B). Taken together, these data demon-
strate that FoxO1/3/4 expression modulates LIC activity in vivo.
Constitutive Activation of Akt Does Not Alter Disease
Latency In Vivo
We examined the effects of expressing myr-Akt in MLL-AF9-
induced leukemia cells in vivo. BM cells derived frommice trans-
formed with MLL-AF9 were infected with either control or myr-
Akt recombinant retroviruses that also express GFP. Following
infection, GFP+ cells from each condition were isolated by
FACS and separately injected into syngeneic recipients. Mice
from all conditions succumbed to AML, and we did not observe
any significant difference in latency between control and myr-
Akt-expressing AMLs (Figure S5H). The lack of impact on latency
was unexpected and caused us to examine whether a mecha-
nism of resistance to Akt activation had emerged.
Inhibition of FOXO3 Results in Activated JNK/c-JUN
Signaling
To evaluate the downstream molecular events that regulate
myeloid maturation of leukemic cells in response to FOXO inhibi-
tion, we examined the status of multiple signaling pathways
involved in myeloid differentiation. Phosphorylation of ERK,
AKT, and c-JUN was assessed upon shRNA-mediated inhibitionCell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc. 703
Figure 5. Deletion of FoxO Transcription Factors Suppresses MLL-AF9-Induced Leukemia In Vivo
(A) Experimental scheme used in Figures 5B–5H where MLL-AF9+ FoxO1/3/4floxed murine bone marrow (BM) cells recovered from a leukemic primary recipient
mouse carrying theMx1-Cre transgene (Cre+) or not (Cre) were transplanted into recipient mice. Cre+ and Cremice were administered saline or pI-pC and then
all mice from each Cre condition were assessed for leukemic burden (day 29 for Cre and day 39 for Cre+).
(B) Mean spleen weight of Cre+ (pI-pC) versus Cre+ (saline) (p < 0.0001; n = 4). Data represented as the mean ± SEM.
(C) Gross anatomical view of spleens recovered from Cre+ mice administered pI-pC (right) or saline (left).
(D) WBC analysis of peripheral blood collected every 4–14 days post-transplant from Cre+ saline- and pI-pC-treated mice (n = 4).
(E and F) Kaplan-Meier survival curve analysis of mice transplanted and treated as described above (E: Cre, p = 0.6899; n = 6 and F: Cre+, p = 0.0009; n = 10).
(G) Leukemic BM cells isolated from Cre+ mice administered saline or pI-pC 7 days earlier were analyzed for the mean proportion ± SEM of L-GMPs (lineagelow,
Sca-1, cKithigh, CD34+, FcgRII/III+, p = 0.039; n = 3).
(H and I) Leukemic BM cells isolated from Cre+ mice administered saline (H) or pI-pC (I) 7 days earlier were transplanted into tertiary recipients at various cell
numbers: 300 (n = 6), 3,000 (n = 6), 30,000 (n = 4), and 300,000 (n = 4). Kaplan-Meier analysis of animals that developed leukemia is shown. LIC frequencies were
calculated using poisson statistics (H: LICfreq+/+ = 1:5,314 and I: LICfreqD/D = 1: 86,044).
See also Figure S5.of FOXO3 expression in MOLM-14 and SKM-1 cells. Although
FOXO3 depletion did not have a substantial effect on AKT or
ERK phosphorylation, serine 63 phosphorylation within c-JUN
(pc-JUNSer63) was elevated in both cell lines (Figure S6A). The
c-JUN oncogene is a member of the AP-1 family of transcription
factors that is phosphorylated and activated by the stress-
activated kinase SAPK/JNK (hereafter JNK) (De´rijard et al.,
1994; Hibi et al., 1993). Under various forms of stress, JNK is704 Cell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc.phosphorylated at threonine 183/tyrosine 185 (pJNKThr183/Tyr185)
(De´rijard et al., 1994). Depletion of FOXO3 resulted in sub-
stantial increases in pJNKThr183/Tyr185, pc-JUNSer63, and total
c-JUN (Figure 6A and Figure S6B). Enforced expression of
myr-Akt in murine MLL-AF9-expressing AML cells led to in-
creased phosphorylation of FoxO3Ser256 (pFoxO3Ser256) as well
as increases in pJnkThr183/Tyr185, pc-JunSer63, and total c-Jun
(Figure 6D).
Figure 6. The JNK/c-JUN Signaling Pathway Antagonizes Maturation and Apoptosis Mediated by FOXO Inhibition in AML
(A) MOLM-14 cells stably expressing either nontargeting (NT) or FOXO3 (FOXO3-1) shRNA were subjected to western blotting with antibodies that specifically
recognize FOXO3, c-JUN, JNK, Tubulin, or the phosphorylated forms of c-JUN (pc-JUNS63) and JNK (pJNKT183/Y185).
(B and C) MOLM-14 cells stably expressing nontargeting (NT) or FOXO3 (F3-1) shRNA were treated with 10 mM SP600125 (JNK inhibitor) or vehicle. Forty-eight
hours later, cells from each condition were assessed for cell number (B, NT [vehicle] versus NT [SP600125], *p = 0.0095, NT [SP600125] versus F3-1 [vehicle],
**p = 0.0008, F3-1 [vehicle] versus F3-1 [SP600125], ***p < 0.0001) and Annexin V staining (C, NT [vehicle] versus NT [SP600125], *p = 0.0282, NT [SP600125]
versus F3-1 [vehicle], **p = 0.0133, F3-1 [vehicle] versus F3-1 [SP600125], ***p = 0.0002). Data are represented as the mean ± SD.
(D) Control and myr-Akt-expressing MLL-AF9+ leukemia BM cells were subjected to western blotting with FoxO3, c-Jun, Jnk, Tubulin, or the phosphorylated
forms of FoxO3 (pFoxO3S256), c-Jun (pc-JUNS63), and Jnk (pJnkT183/Y185) antibodies.
(E and F) Control and myr-Akt-expressing MLL-AF9+ leukemia BM cells were treated with 10 mM SP600125 (JNK inhibitor) or vehicle. Forty-eight hours after
treatment, cells from each condition were assessed for cell number (E, Ctrl [vehicle] versus Ctrl [SP600125], *p = 0.0373, Ctrl [vehicle] versus myr-Akt [vehicle],
**p = 0.0381,myr-Akt [vehicle] versusmyr-Akt [SP600125], ***p < 0.0001) and Annexin V staining (F, Ctrl [SP600125] versusmyr-Akt [vehicle], *p = 0.0011, myr-Akt
[vehicle] versus myr-Akt [SP600125], **p < 0.0001). Data are represented as the mean ± SD.
See also Figure S6.Pharmacological Inhibition of JNK Cooperates with
FOXO Inhibition to Induce AML Cell Death
We then tested whether JNK/c-JUN signaling has a functional
impact on cellular events induced by AKT and FOXO signaling.
We combined a pan-JNK inhibitor (SP600125, Calbiochem)
with either FOXO3 depletion or myr-Akt expression and evalu-
ated the growth, differentiation, and survival of AML cells. Treat-
ment of control-infected MOLM-14-, SKM-1-, or MLL-AF9-
expressing murine leukemia cells with SP600125 caused
a modest but significant decrease in cell growth and a mild
increase in mature myeloid surface marker expression and
apoptosis (Figures 6B, 6C, 6E, and 6F; Figures S6C–S6E). As
seenpreviously, depletion of FOXO3ormyr-Akt resulted in signif-
icant decreases in cell growth and increases in mature myeloid
surface marker expression and apoptosis (Figures 6C and 6F;
Figures S6C–S6E). Notably, the combination of SP600125 with
either FOXO3 depletion ormyr-Akt expression led to a significant
decrease in cell growth and increases in apoptosis and mature
myeloid surfacemarker expression compared to FOXO3 shRNA,
myr-Akt expression, or SP600125 treatment alone (Figures 6B,
6C, 6E and 6F; Figures S6D–S6F). Furthermore, SP600125 com-
bined with myr-Akt resulted in morphological changes associ-
ated with myeloid differentiation (Figure S6F). Together, these
data suggest that FOXO3 inhibition or AKT activation in AML
results in JNK/c-JUN pathway activation mitigating the antileu-
kemic properties of FOXO3 inhibition or AKT activation.c-JUN Activity Is Elevated in AMLs with Diminished
FOXO Activity
As JNK/c-JUN signalingwas activated in response to FOXO inhi-
bition (directly or via Akt activation), we examined whether acti-
vation of this pathway was also initiated in vivo. Analyzing the
phosphorylation status of c-Jun in FoxO1/3/4floxed (saline) and
FoxO1/3/4D/D (pI-pC) leukemic BM cells recovered from mice
(Figure 5F) with AML, we observed increased pc-JunSer63 in
75% of mice that died of AML despite efficient deletion of
FoxO1/3/4 (Figure 7A and Figures S5C–S5F). We also evaluated
the phosphorylation status of BM cells derived from control and
myr-Akt-expressing leukemic mice from Figure S5H. Leukemic
BM from four mice that succumbed to AML expressing MLL-
AF9 and myr-Akt displayed elevated pc-JunSer63 compared to
control leukemic BM (Figure 7B). Furthermore, all four myr-Akt-
expressing AMLs displayed increases in pFoxO3Ser256, con-
firming that myr-Akt was inhibiting FoxO3 in these tumors
(Figure 7B).
To get a broader understanding of the relationship between
FOXO inhibition and JNK/c-JUN activation in human AML, the
expression of c-JUN was determined in the gene expression
array dataset generated from 436 primary AML patient samples.
c-JUN expression inversely correlated with FOXO activity and
FOXO1 and FOXO3 expression (p < 0.0001; Figure 7C). Collec-
tively, these data demonstrate that inhibition of the AKT/FOXO
signaling pathway preserves the immature phenotype and theCell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc. 705
Figure 7. c-JUN Activity Is Upregulated in
AMLs Displaying Constitutive AKT Activa-
tion or FOXO Inhibition
(A) BM cells recovered from mice that succumbed
to MLL-AF9-induced AML (refer to Figure 5F) that
were wild-type or null for FoxO1/3/4 were sub-
jected to western blotting with pc-JunS63 and
Tubulin antibodies.
(B) BM cells recovered frommice that succumbed
to control or myr-Akt-expressing MLL-AF9-in-
duced AML (refer to Figure S5G) were subjected to
western bloting with antibodies that recognize Akt,
Tubulin, or the phosphorylated forms of FoxO3
(pFoxO3S256) or c-Jun (pc-JunS63) antibodies.
(C)Mean expression levels of FOXO1, FOXO3, and
c-JUN in the FOXO signature-based, hierarchi-
cal cluster-defined primary AML sample groups
(p < 0.0001; see Figure 4G). Data are represented
in a box plot with whiskers.leukemia-initiating properties of various AML subtypes. These
data also suggest that activation of the JNK/c-JUN pathway
represents a common mechanism by which AML tolerates the
deregulation of FOXO/AKT signaling and offers a therapeutic
opportunity of targeting deregulated JNK/c-JUN signaling in
FOXO/AKT-deregulated AML.
DISCUSSION
In many human cancers, the serine/threonine kinase AKT
promotes tumorigenesis by phosphorylating and inactivating
targets that antagonize malignant growth, such as the FOXO
family of transcription factors. We have identified an unex-
pected, yet crucial role of the FOXO signaling arm of the AKT
pathway in the maintenance of the differentiation blockade in
AML. We observed that Akt is repressed and FoxO1/3/4 are
active in the MLL-AF9 AML cell fraction most highly enriched
for LIC activity. Further, enforced activation of Akt or deletion
of its canonical downstream targets, FoxO1, FoxO3, and
FoxO4 (FoxO1/3/4—thought to be tumor suppressors), de-
crease leukemic growth and maintenance in vitro by promoting
myeloid maturation and apoptosis. Ablation of FoxO1/3/4 in vivo
reduced disease burden, diminished LIC function, and extended
the life span of animals transplanted with MLL-AF9-positive
AML. We confirmed the clinical relevance of our findings by
demonstrating that FOXOs are active in primary samples derived
from AML patients.706 Cell 146, 697–708, September 2, 2011 ª2011 Elsevier Inc.Wehave also identified amechanismof
resistance to inhibiting FOXOs. Leuke-
mias that persisted despite FoxO1/3/4
deletion or constitutive Akt activation ex-
hibited c-Jun activation. Pharmacolog-
ical inhibition of JNK augmented the
myeloid maturation and apoptotic effects
ofAkt activationor FOXO inhibition. These
data were supported by patient data
where we noted that AML samples with
reduced FOXO activity had increased
expression of c-JUN. Taken together, the data suggest an
inverse correlation of FOXO and JNK/c-JUN activation in AML,
and that whereas FOXO depletion can induce a therapeutic
differentiation of AML cells, increased JNK/c-JUN activity can
render cells insensitive to FOXO loss. A combination of reduced
FOXO and JNK/c-JUN activation may provide a particularly
potent approach to AML.
The previously unrecognized relationship whereby blocking
FOXO activity via direct inhibition or Akt activation activates
JNK/c-JUN signaling is quite distinctive from prior reports that
AKT inhibits JNK by inhibiting the JNK-activating kinase ASK1
(Kim et al., 2001). Also, others noted that JNK can regulate
FOXOs,particularly FOXO4,butweare unawareof prior evidence
that FOXOs can inhibit JNK signaling (Essers et al., 2004; Wang
et al., 2005). Our data suggest that this relationship of AKT/
FOXOs to JNK/c-JUN is associated with AML surviving the acti-
vation of Akt and/or inhibition of FOXOs. These findings provide
a rationale for considering JNK inhibition in antileukemic therapy.
It is not clear whywe observed divergence between the results
of Akt activation and FOXO inhibition on leukemia outcomes
in vivo. However, it may be that some growth-promoting activi-
ties of Akt (such as activation of mTorc1 or inactivation of
Gsk-3b) may provide countervailing signals in vivo that abrogate
the effects of FoxO inhibition (Lee et al., 2010; Wang et al., 2008;
Yilmaz et al., 2006).
The genetic andmolecular heterogeneity of AML hasmade the
development of universal targeted therapies cumbersome and
relatively unsuccessful. The broad bifurcation we have observed
of AMLs based on their AKT, FOXO, and c-JUN signaling
coupled with the impact that altering these pathways has on
leukemia-initiating cells suggests a possible therapeutic oppor-
tunity for the development of more widely acting antileukemic
agents.
EXPERIMENTAL PROCEDURES
Plasmid and Mouse Generation
The MSCV-MLL-AF9 construct was a kind gift of Dr. S.A. Armstrong (Chil-
dren’s Hospital of Boston—CHOB). The MSCV-IRES-GFP-myr-Akt construct
was kindly provided by Dr. K. Gritsman (Dana-Farber Cancer Institute) and
Dr. Michael G. Kharas (CHOB). The MSCV-puro-CreER plasmid was kindly
donated by Dr. D. Kalaitzidis (CHOB). The expression plasmid carrying the
LSL-hCD34 was kindly donated by Dr. M. Milsom (Heidelberg University).
The FoxO1/3/4floxed;Mx1-Cre+ mice were generated previously (Paik et al.,
2007; Tothova et al., 2007).
AML Patient Samples
BM aspirates from patients with AML were collected under a protocol
approved by the institutional review board (IRB) of Massachusetts General
Hospital. Ficoll density gradient was then used to recover viable mononuclear
cells from BM aspirates.
MLL-AF9 Retroviral Bone Marrow Transplantation Assay
Both FoxO1/3/4floxed;Mx1-Cre+ and FoxO1/3/4floxed;Mx1-Cre mice were
administered 150 mg/kg 5-flurouracil (5-FU, Sigma). Recovered mononuclear
bone marrow cells (MNBCs) were transduced with recombinant MLL-AF9-
expressing retroviruses and transplanted into lethally irradiated F1 FVB/C57/
Bl6mice. Recipient mice developed leukemia within 70–80 days with amedian
survival of 77 days. MNBCs recovered from leukemic mice were then trans-
planted into secondary sublethally irradiated recipients. Fourteen days after
transplant, secondary recipients were administered intraperitoneally three
doses of saline or 12.5 mg/kg pI-pC (Amersham) every 2 days. Mice were
then monitored for external (i.e., moribund) and internal (white blood cell
counts) signs of leukemia.
Flow Cytometry and Antibodies
MNBCs were stained with a lineage cocktail comprised of antibodies targeting
CD3, CD4, CD8, CD19, B220, Gr-1, Ter119, and IL-7Ra. MNBCs were also
stained with antibodies targeting cKit, Sca-1, FcgRII/III, and CD34. L-GMP
and GMP populations were analyzed and sorted with a FACSAria instrument
(Becton Dickinson). For phosphoflow experiments, lineagelow cells were
sorted and stained with cKit and CD34 antibodies in combination with phos-
pho-AKTSer473, phospho-AKTThr308, or phospho-S6Ser235/236 antibodies and
then analyzed on a FACSAria. Primary AML patient BM cells were stained
with human CD34 and lineage cocktail. Antibody information including
company, clone, and dilution factor are listed in Table S2.
Cell Death Assays
Cells were stained with Annexin V and 7-AAD according to the manufacturer
instructions (BD Biosciences) to assess levels of apoptosis. Where indicated,
cell death was also evaluated with Trypan Blue staining (Cellgro).
Phagocytosis Assay
Phagocytosis was assessed using a pHrodo BioParticles Conjugates for
Phagocytosis Kit (Invitrogen). Assays were performed according to the manu-
facturer’s instructions.
Indirect Immunofluorescence
Cytospins of purified L-GMPs and GMPs were fixed with PFA and permeabi-
lized with methanol. Processed cells were then subjected to staining with
FOXO3 (75D8) antibodies. Cells were then incubated with an anti-rabbit
FITC-conjugated secondary antibody (1:2000; Sigma). Cells were also stainedwith DAPI to visualize nuclei and visualized under 1003 magnification using
a Nikon fluorescence microscope.
Cell Fractionation
Cells were resuspended in hypotonic buffer containing a mild detergent to
rupture cellular membrane. Recovered nuclei lysed in a hypertonic solution
and cytoplasmic fractions were subjected to western blotting with the corre-
sponding antibodies.
Cell Morphology Staining
Cells from respective conditionswere stained first withMay-Gru¨nwald dye and
then Giemsa stain (Sigma). Alternatively, cells were permeabilized and stained
in 100%Wright-Giemsa stain and then stained with 20%Wright-Giemsa/80%.
Colony Assays
Murine myeloid colony assays were plated in M3434 cytokine-enriched meth-
ylcellulose according to manufacturer’s instructions (Stem Cell Technologies).
Human myeloid colony assays were plated in H4034 cytokine-enriched meth-
ylcellulose according to manufacturer’s instructions (Stem Cell Technologies).
For CAFC assays, murine leukemia cells were cocultured on OP9 stroma cells
for 7–14 days.
Statistical Analyses
Log-rank (Mantel-Cox) test was used to determine p values for all Kaplan-
Meier survival curve analyses. Unpaired, two-tailed Student’s t tests were
used for all analyses comparing two experimental groups. Poisson statistics
was used to determine the LIC frequency in vivo in Figures 5H and 5I as well
as in vitro in Figures S2E and S2F.
Additional experimental details can be found in the Extended Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and two tables and can be found with this article online at doi:10.
1016/j.cell.2011.07.032.
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